GRIFOLS S A/S (NASDAQ:GRFS) Receives $20.75 Consensus PT from Analysts

GRIFOLS S A/S (NASDAQ:GRFS) has been given an average rating of “Hold” by the eight brokerages that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, three have issued a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $20.75.

A number of research analysts have recently commented on GRFS shares. JPMorgan Chase & Co. raised GRIFOLS S A/S from a “neutral” rating to an “overweight” rating and raised their price target for the company from $21.00 to $22.50 in a report on Thursday, June 27th. Zacks Investment Research raised GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. ValuEngine lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Thursday, August 1st. Finally, BidaskClub raised GRIFOLS S A/S from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd.

GRFS stock traded up $0.09 during mid-day trading on Thursday, reaching $21.87. The company had a trading volume of 762,100 shares, compared to its average volume of 1,119,278. The company has a quick ratio of 0.95, a current ratio of 2.68 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $15.14 billion, a PE ratio of 18.77, a P/E/G ratio of 1.36 and a beta of 1.11. GRIFOLS S A/S has a one year low of $17.42 and a one year high of $23.03. The business has a 50-day moving average price of $21.75.

Several institutional investors and hedge funds have recently modified their holdings of GRFS. Blackhawk Capital Partners LLC. acquired a new position in shares of GRIFOLS S A/S during the second quarter valued at $254,000. United Capital Financial Advisers LLC increased its holdings in GRIFOLS S A/S by 4.7% in the second quarter. United Capital Financial Advisers LLC now owns 729,097 shares of the biotechnology company’s stock valued at $14,998,000 after purchasing an additional 32,611 shares during the last quarter. Maven Securities LTD bought a new stake in GRIFOLS S A/S in the second quarter valued at about $494,000. Parametric Portfolio Associates LLC increased its holdings in GRIFOLS S A/S by 9.5% in the second quarter. Parametric Portfolio Associates LLC now owns 691,154 shares of the biotechnology company’s stock valued at $14,583,000 after purchasing an additional 59,969 shares during the last quarter. Finally, Impax Asset Management Group plc increased its holdings in GRIFOLS S A/S by 9.6% in the second quarter. Impax Asset Management Group plc now owns 563,002 shares of the biotechnology company’s stock valued at $11,879,000 after purchasing an additional 49,133 shares during the last quarter. 19.14% of the stock is currently owned by institutional investors.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

See Also: How do analysts define an oversold condition?

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.